What Entrada Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 17 |
| Sells | 33 | 44 |
| Total trades | 37 | 78 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 522,511 |
| Disposed | 1,457,972 | 2,020,201 |
| Net activity | −1,457,972 | −1,497,690 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Mpm Bioventures 2018, L.p. | 10% owner | Sep 09 | Open-market sale · S | −28,837 | $7.13 | −$206K | 3,885,115 |
| Mpm BioVentures 2014, L.p. | 10% owner | Sep 09 | Open-market sale · S | −28,837 | $7.13 | −$206K | 3,885,115 |
| Mpm Bioventures 2018, L.p. | 10% owner | Sep 08 | Open-market sale · S | −192,500 | $7.41 | −$1.43M | 3,913,952 |
| Mpm BioVentures 2014, L.p. | 10% owner | Sep 08 | Open-market sale · S | −192,500 | $7.41 | −$1.43M | 3,913,952 |
| Mpm Bioventures 2018, L.p. | 10% owner | Sep 04 | Open-market sale · S | −38,500 | $7.11 | −$274K | 4,106,452 |
| Mpm BioVentures 2014, L.p. | 10% owner | Sep 04 | Open-market sale · S | −38,500 | $7.11 | −$274K | 4,106,452 |
| Mpm BioVentures 2014, L.p. | 10% owner | Sep 03 | Open-market sale · S | −32,263 | $7.17 | −$231K | 4,144,952 |
| Mpm Bioventures 2018, L.p. | 10% owner | Sep 03 | Open-market sale · S | −32,263 | $7.17 | −$231K | 4,144,952 |
| Wentworth Kory James | Chief Financial Officer | Sep 02 | Withheld — tax / exercise cost · F | −1,733 | $7.14 | −$12.4K | 117,277 |
| Sethuraman Natarajan | President, Research & Develop. | Sep 02 | Withheld — tax / exercise cost · F | −2,079 | $7.14 | −$14.9K | 214,238 |
| Dowden Nathan J | President & COO | Sep 02 | Withheld — tax / exercise cost · F | −2,528 | $7.14 | −$18.1K | 196,060 |
| Mpm BioVentures 2014, L.p. | 10% owner | Sep 02 | Open-market sale · S | −25,131 | $7.19 | −$181K | 4,177,215 |
| Doshi Dipal | CEO | Sep 02 | Withheld — tax / exercise cost · F | −8,724 | $7.14 | −$62.3K | 517,290 |
| Mpm Bioventures 2018, L.p. | 10% owner | Sep 02 | Open-market sale · S | −25,131 | $7.19 | −$181K | 4,177,215 |
| Mpm BioVentures 2014, L.p. | 10% owner | Sep 01 | Open-market sale · S | −29,088 | $7.06 | −$205K | 4,202,346 |
| Mpm Bioventures 2018, L.p. | 10% owner | Sep 01 | Open-market sale · S | −29,088 | $7.06 | −$205K | 4,202,346 |
| Mpm Bioventures 2018, L.p. | 10% owner | Aug 31 | Open-market sale · S | −44,259 | $6.99 | −$309K | 4,231,434 |
| Mpm BioVentures 2014, L.p. | 10% owner | Aug 31 | Open-market sale · S | −44,259 | $6.99 | −$309K | 4,231,434 |
| Mpm Bioventures 2018, L.p. | 10% owner | Aug 28 | Open-market sale · S | −3,733 | $7.01 | −$26.2K | 4,275,693 |
| Mpm BioVentures 2014, L.p. | 10% owner | Aug 28 | Open-market sale · S | −3,733 | $7.01 | −$26.2K | 4,275,693 |
Loading...